Sikolat Medical Completes Tens of Millions RMB Series A Funding to Mass-Produce Next-Generation High-Reliability CT Tubes

VCBeat has learned that Skyray Medical Technology (Suzhou) Co., Ltd., a developer and manufacturer of CT X-ray tubes, recently completed its Series A financing round, raising tens of millions of RMB. The round was led by Yanying Investment and Taicang Gang Hongli Investment, with existing investors Lead Wealth Capital and Shenzhen Oriental Fortune Capital participating in the follow-on investment.

Skylight stated, “The funds raised in this financing round will be used for the development and mass production of next-generation CT X-ray tubes.”

According to available information, Skylight Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as “Skylight”) is currently focused on the research, development, and manufacturing of CT X-ray tubes, aiming to address China’s shortcomings in core CT components by establishing a series of high-power CT X-ray tube products with full independent intellectual property rights that are ready for mass production. In the future, its product pipeline will also include vacuum power devices and high-energy radiation detectors.

Currently, Skyray’s 3.5 MHU and 5 MHU anode heat capacity CT X-ray tubes have achieved mass production and commercial sales. They are widely installed in various models of CT scanners at hospitals both in China and abroad, earning acclaim and preference from domestic and international customers thanks to their high reliability and systematic customer service.

During the current special period of the global fight against the COVID-19 pandemic, the consumption of CT X-ray tubes has doubled. Skylight provides solid support with its high-heat-capacity, highly reliable, and cost-effective CT X-ray tubes.

Sikolate stated, “The company will continue to broaden the breadth and depth of its product portfolio in accordance with its established product roadmap, serving customers and giving back to society with pragmatism and rationality.”

Scolat’s core team possesses over a decade of R&D, process engineering, and marketing experience from large multinational medical device companies. They have a profound understanding of the design of vacuum components such as CT X-ray tubes and are well-versed in both domestic and international supply chains. Building on this foundation, after four years of innovation, improvement, and optimization, Scolat has obtained registration certification for medical diagnostic rotating anode X-ray tubes and achieved small-batch exports and domestic sales. Furthermore, through continuous innovation and iterative optimization, Scolat’s products have reached technical specifications and reliability levels comparable to those of multinational corporations, earning widespread acclaim in the industry for its overseas shipments.

Yu Shan, founder of Skylight, revealed: “This year, the company plans to commence large-scale mass production and will further expand production capacity in the near future. We are committed to continuously providing high-performance, stable, and reliable CT X-ray tubes, adhering to Konosuke Matsushita’s ‘Tap Water Philosophy’ by delivering cost-effective products to serve the global market.”

Chen Hao, President of Xiangtang Group and Chief Investment Officer of Yanying InvestmentHe stated, “In recent years, the localization of complete large-scale medical equipment has accelerated; however, core components remain constrained by a handful of foreign manufacturers, preventing domestically produced devices from realizing their cost advantages. The X-ray tube is the primary bottleneck in CT systems. We have observed that the Skylight team has been deeply engaged in the CT X-ray tube sector for many years, accumulating extensive design and manufacturing expertise. We hope that following this round of financing, Skylight will accelerate its development and expand into the vast domestic and international markets.”

Ji Tian, Founding Partner of Lead Wealth Capitalstated: “Scolat’s unique technology and market positioning, along with the team’s high-standard and high-speed industrialization capabilities, have exceeded our expectations. This additional investment reflects Lead Wealth Capital’s strong confidence in the significant opportunities for localizing core technologies of imported medical devices in China. We also wish the company even greater and faster growth!”

Wang Peijun, Partner at Oriental Fortune CapitalShenzhen Oriental Fortune Capital stated: “We closely monitor the ‘chokepoint’ areas in China’s medical device and equipment sectors. We seek to establish long-term, mutually beneficial partnerships with entrepreneurs who possess strong technical expertise, a deep commitment to the industry, and a spirit of craftsmanship. We sincerely wish Skyray continued success in achieving the industrialization of its medical CT X-ray tube series, while actively expanding into the fields of industrial CT X-ray tubes and other core vacuum components—areas where domestic supply is scarce and reliance on imports remains high. In doing so, Skyray will contribute to enhancing the core competitiveness of China’s high-end CT equipment, particularly in terms of autonomous controllability, cost-effectiveness, and supply chain integrity.”

Yanying Investment is a professional investment institution under the Suzhou Xiangtang Group, with investment areas including biopharmaceuticals, medical devices, and medical diagnostics. Over the years, Xiangtang Group has focused on investments in biomedicine and medical technology, prioritizing various unmet clinical needs. It possesses unique perspectives and clear judgment in selecting investment projects. Xiangtang maintains close collaboration with its portfolio companies, providing not only financial support but also assistance in business expansion, thereby growing together with these enterprises. Currently, the total asset scale invested by Xiangtang Group exceeds several billion yuan.

Lead Wealth Capital, originating from Fudan University, focuses on venture capital and growth-stage investments in medical technology and other high-tech sectors. The firm strategically targets technology-driven enterprises in niche segments such as high-end medical devices, immunotherapy, cell therapy, and gene therapy. In the realm of medical services, particularly oncology treatment, it prioritizes sectors with significant patient-entry value and clinical value.

Shenzhen Oriental Fortune Capital Co., Ltd. (hereinafter referred to as “OFC” or “Oriental Fortune Capital”) is a professional venture capital management firm founded by several industry experts with extensive experience, proven track records, outstanding investment performance, and significant influence in China’s venture capital sector. Adopting international best practices, OFC has established its own operational framework characterized by rigorous and meticulous management, efficient investment decision-making, and the ability to provide customized value-added services to portfolio companies as needed. Since its inception, the company has managed a cumulative fund size of nearly RMB 25 billion, with 52 funds currently under management. It has invested in over 480 projects, with 125 exits achieved through IPOs, mergers and acquisitions, and other channels. OFC is committed to investing in high-growth companies with IPO potential, actively providing value-added services to enhance their profitability, and striving to help them maximize enterprise value through pathways such as IPOs, thereby delivering satisfactory capital appreciation returns to investors.